CRISPR Therapeutics

US · CRSP #2057 by market cap Listed 2016

52.35 -1.65 -3.06%

Live - 5344 symbols - heartbeat 2s ago · 2026-10-08 08:20

Pre-market 51.53 -1.57%

After-hours 52.65 +0.57%

Overnight 52.09 -0.50%

Market cap: 5.06B
P/E (TTM): -11.11
P/B: 2.90
EPS: -6.47
Div yield: 0.00%
52W pos: 27%

Reader sentiment Are you bullish or bearish on CRSP?

Anonymous reader poll. Unscientific, not investment advice.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a gene editing company, which engages in the development of transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. Its CRISPR/Cas9 platform is a gene editing technology that allows for precise, directed changes to genomic DNA. The firm offers a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company was founded by Rodger Novak, Emmanuelle Charpentier, Shaun Patrick Foy, Matthew Porteus, Daniel Anderson, Chad Cowan, and Craig Mellow on October 31, 2013 and is headquartered in Zug, Switzerland.

Founded: 2013
CEO: Dr. Samarth Kulkarni, PhD
Employees: 393
Headquarters: Zug, Zug, Switzerland
Fiscal year end: 12-31
Website: crisprtx.com

Company profile

Exchange: US
Symbol: CRSP
Market-cap rank: #2057
Listing date: 2016-10-19
Market cap: 5.06B
Float cap: 5.04B
Shares out: 96.69M
Float shares: 96.26M

Sectors & themes

Biotechnology ARK Portfolio AI medical concept stocks Gene Editing Global medical industry Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 08:20:18 · For reference only, not investment advice and not tailored to your situation.